Navidea Biopharmaceuticals to Announce Second Quarter 2013 Financial Results Pre-market on Wednesday
Navidea Biopharmaceuticals to Announce Second Quarter 2013 Financial Results Pre-market on Wednesday, August 7, 2013
- Conference call with investment community to follow -
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that the Company will report its financial results for the second quarter of 2013, on Wednesday, August 7, 2013 before the market opens. The announcement will be followed by a conference call with the investment community, also on Wednesday, August 7, 2013, at 8:30 a.m. EDT, to provide a business update and discuss the Company's financial and operational results.
Investors and the public are invited to listen live to the call. If you are unable to join the live call, an archived version will be available until August 21, 2013. The conference call can be accessed as follows:
CONFERENCE CALL INFORMATION | |||||||||||||||||
TO PARTICIPATE LIVE: | TO LISTEN TO A REPLAY: | ||||||||||||||||
Date: Time: Toll-free (U.S.) Dial in #: International Dial in #: | August 7, 2013 8:30 a.m. EDT (877) 407-8031 (201) 689-8031 | Available until: Toll-free (U.S.) Dial in #: International Dial in #: Replay passcode: Account #: Conference ID #: | August 21, 2013 (877) 660-6853 (201) 612-7415 268 418275 | ||||||||||||||
About Navidea Biopharmaceuticals Inc.
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents. Navidea is actively developing four radiopharmaceutical agent platforms - Lymphoseek®, NAV4694, NAV5001 and RIGScanTM - to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making and, ultimately, patient care. Navidea's strategy is to deliver superior growth and shareholder return by bringing to market novel radiopharmaceutical agents and advancing the Company's pipeline through selective acquisitions, global partnering and commercialization efforts. For more information, please visit www.navidea.com.
Navidea Biopharmaceuticals, Inc.
Brent Larson, 614-822-2330
Executive VP & CFO
or
Stern Investor Relations, Inc.
Beth DelGiacco, 212-362-1200
KEYWORDS: United States North America Ohio
INDUSTRY KEYWORDS:
The article Navidea Biopharmaceuticals to Announce Second Quarter 2013 Financial Results Pre-market on Wednesday, August 7, 2013 originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
